Novo Nordisk Reduces Prices for Wegovy and Ozempic for Some Consumers

Danish pharmaceutical company Novo Nordisk has decided to lower the cost of its popular weight management medications, Wegovy and Ozempic, for certain buyers.

Individuals currently purchasing these medications without insurance support will notice their monthly costs decrease to $349 from the previous price of $499, according to Novo Nordisk's recent announcement.

Moreover, the company is introducing a special rate for new customers who are paying out of pocket. They will be charged $199 monthly for the initial two months of treatment. Following that period, the price will revert to $349 per month. This introductory rate of $199 is available until March 31, 2026.

The revised pricing strategy for those paying directly for their slimming medications coincides with initiatives supported by the previous U.S. administration. An agreement confirmed earlier this month stated that individuals using Medicare, Medicaid, and accessing the pharmaceutical website will be eligible for reduced prices on Novo Nordisk's GLP-1 medications, alongside Eli Lilly's Zepbound.

According to Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk, the firm aims to ensure that these medications remain within reach for individuals who require them.